Kyowa Hakko Kogyo Co having its headquarters in Tokyo, Japan is considered to be one of the most reputed and renowned inventor, producer and marketer of pharmaceutical and biotechnological products since more than five decades now. The company is leading in the advancement and application of fermentation technology as well as innovative kinds of biotechnology. The company’s key pharmaceutical research has been targeted on the drug discovery through support of antibody techniques and developing therapeutic agents for cancer and allergic disorders.

 

Kyowa Hakko has obtained universal triumph with a couple of agents such as: Mitomycin which is designated for adenocarcinoma of the stomach and the pancreas and is being sold in the United State markets through Bristol-Myers Squibb under the brand name as Mutamycin. The other agent is Olopatadine which is meant to ease itching of the eyes caused because of allergic conjunctivitis and sold in the United States through Alcon under the brand called Patanol.        

 

Basically the company is actively manufacturing pharmaceuticals and chemicals and its operations are managed through different divisions such as: Pharmaceuticals, Bio-chemicals, Chemicals, Foods and others. Pharmaceuticals incorporate ethical drugs, bulk drugs and biological research. Bio-chemicals division handles the bio-chemical diagnostic reagents, animal health products, agrochemicals and fertilizers. Chemical division incorporates solvents, plasticizes and its raw materials detergent raw materials and specialty chemicals. Food division covers alcoholic beverages, alcohol, seasonings, confectionery, baking materials and processed foods while others take care of distribution of wholesale commodity and installation facilities.         

 

The company is immensely acknowledged for providing many therapeutic drugs like: Coniel – for treating hypertension and angina pectoris, Neu-up for treating Neutropenia and anti-allergic drug called Allelock.